Through its US-based subsidiary AMDL Diagnostics Inc, Radient Pharmaceuticals Corporation (RPC)'s executive management would be in India from May 20 to May 25, 2010 with the goal accelerating the commercialization of RPC’s Onko Sure in vitro diagnostic (IVD) cancer test in India through distribution partnerships with Gaur Diagno (New Delhi).
More specifically, RPC’s executive management team will be solidifying expanded partnership agreements for the sales and marketing of Onko Sure test kits with Gaur Diagno; and the development of clinical trails for RPC’s Combination Immunogene Therapy (CIT) technology with Jaiva Technologies.
According to Douglas MacLellan, chairman and CEO of Radient Pharmaceuticals, "Measurable progress for Onko Sure cancer testing is of the utmost importance for Radient Pharmaceuticals and its employees, customers, partners and shareholders. We have scheduled meetings with a highly anticipated program launch with key government officials in India in support of the commercialization of our US FDA approved Onko Sure IVD cancer test. Through discussions, we anticipate receiving Indian government support in various regions to implement Onko Sure as a general cancer screening tool in India ? one of the first major initiatives for Onko-Sure as a cancer testing/screening tool. India is top tier market for RPC’s Onko Sure IVD cancer test.”
Onko Sure is a simple, non invasive, patent pending and regulatory approved in vitro test for use as an aid in early detection of cancer that enables physicians and their patients to effectively monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP).
CIT is a proprietary, US-patented technology owned by Radient Pharmaceuticals. Used as a cancer therapy and vaccine, CIT both builds the body's immune system and destroys cancers simultaneously.
Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of in vitro diagnostic products.
Gaur Diagno is an New Delhi, India based pharmaceutical distributor.
Jaiva Technologies is a US-based multinational biotechnology company focused on the research and development, distribution, marketing and sales of promising third party healthcare technology products, including RPC's CIT cancer therapy and vaccine.